Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Deloitte
Chinese Patent Office
Healthtrust
Dow
Federal Trade Commission
Colorcon
Boehringer Ingelheim
Chubb

Generated: May 22, 2018

DrugPatentWatch Database Preview

PROLIXIN ENANTHATE Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Prolixin Enanthate patents expire, and what generic alternatives are available?

Prolixin Enanthate is a drug marketed by Apothecon and is included in one NDA.

The generic ingredient in PROLIXIN ENANTHATE is fluphenazine enanthate. There are eighteen drug master file entries for this compound. Additional details are available on the fluphenazine enanthate profile page.
Summary for PROLIXIN ENANTHATE
Drug patent expirations by year for PROLIXIN ENANTHATE
Synonyms for PROLIXIN ENANTHATE
2-(4-(3-(2-(Trifluoromethyl)phenothiazin-10-yl)propyl)-1-piperazinyl))ethyl heptanoate
2-(4-(3-(2-(Trifluoromethyl)phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl heptanoate
2-(4-(3-[2-(Trifluoromethyl)-10H-phenothiazin-10-yl]propyl)-1-piperazinyl)ethyl heptanoate #
2-(4-{3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl}piperazin-1-yl)ethyl heptanoate
2-[4-[3-[2-(Trifluoromethyl)phenothiazin-10-yl]propyl]-1-piperazinyl]ethyl heptanoate
2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethyl heptanoate
2746-81-8
4-(3-(2-Trifluoromethyl-10-phenothiazinyl)propyl)-1-piperazineethanol enanthate
AC1L1FTQ
AC1Q4K02
AKOS003589053
BRN 0598595
C07955
C29H38F3N3O2S
CCRIS 4033
CHEBI:5125
CHEMBL1200951
CTK4F9745
D00792
DR003241
DTXSID6023070
EINECS 220-385-0
Enanthic acid fluphenazine
Eutimox
Fluphenazine enantate
fluphenazine enanthate
Fluphenazine enanthate (JP17/USP)
Fluphenazine enanthate [JAN]
Fluphenazine enanthate [USP:JAN]
Fluphenazine O-enantate
FT-0737140
Heptanoic acid, 2-(4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl ester
Heptanoic acid, 2-(4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)- 1-piperazinyl)ethyl ester
Heptanoic acid, 2-(4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)-1-piperazinyl)ethyl ester
Heptanoic acid, 2-[4-[3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl]-1-piperazinyl]ethyl ester
Heptanoic acid,2-[4-[3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl]-1-piperazinyl]ethylester
J-016771
LP083419
LRWSFOSWNAQHHW-UHFFFAOYSA-N
LS-74415
Moditen enanthate
Moditen-retard
Prolixin enanthate (TN)
QSB34YF0W9
SCHEMBL120793
SQ 16,114
SQ-16144
UNII-QSB34YF0W9
ZINC22446649

US Patents and Regulatory Information for PROLIXIN ENANTHATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Apothecon PROLIXIN ENANTHATE fluphenazine enanthate INJECTABLE;INJECTION 016110-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Daiichi Sankyo
US Department of Justice
Fish and Richardson
Baxter
Cerilliant
McKesson
Chubb
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.